Arvinas Inc. (ARVN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data
Arvinas NASDAQ: ARVN management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where the company believes it can create differentiated therapies, while seeking partners for assets that may require broader development resources.
Arvinas, Inc. (ARVN) Q1 2026 Earnings Call Transcript
Arvinas, Inc. (ARVN) Q1 2026 Earnings Call Transcript
Arvinas Q1 Earnings Call Highlights
Arvinas NASDAQ: ARVN said its first quarter was marked by the FDA approval of VEPPANU, a new licensing agreement with Rigel Pharmaceuticals and continued progress across a clinical-stage pipeline focused on targeted protein degradation.
Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates
Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to earnings of $1.14 per share a year ago.
Arvinas (ARVN) Expected to Announce Earnings on Thursday
Arvinas (NASDAQ: ARVN - Get Free Report) is anticipated to release its Q1 2026 results before the market opens on Thursday, April 30th. Analysts expect Arvinas to post earnings of ($0.94) per share and revenue of $17.1640 million for the quarter. Individuals may visit the the company's upcoming Q1 2026 earning results page for the latest
Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last?
Arvinas (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Arvinas, Inc. (ARVN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Arvinas, Inc. (ARVN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Arvinas, Inc. (ARVN) Q4 2025 Earnings Call Transcript
Arvinas, Inc. (ARVN) Q4 2025 Earnings Call Transcript
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
Arvinas, Inc. (ARVN) came out with a quarterly loss of $1.1 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.63 per share a year ago.
Arvinas, Inc. (ARVN) Q3 2025 Earnings Call Transcript
Arvinas, Inc. ( ARVN ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Jeff Boyle - Vice President of Investor Relations John Houston - Chairperson, CEO & President Noah Berkowitz - Chief Medical Officer Angela Cacace - Chief Scientific Officer Andrew Saik - CFO & Treasurer Conference Call Participants Etzer Darout - Barclays Bank PLC, Research Division Jeet Mukherjee - BTIG, LLC, Research Division Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Srikripa Devarakonda - Truist Securities, Inc., Research Division Tazeen Ahmad - BofA Securities, Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Jonathan Miller - Evercore ISI Institutional Equities, Research Division Presentation Operator Thank you for standing by, and welcome to Arvinas Third Quarter 2025 Earnings Call. I'd like to remind everyone that this call is being recorded.
Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Arvinas (ARVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript
Arvinas, Inc. (NASDAQ:ARVN ) Q2 2025 Earnings Call August 6, 2025 8:00 AM ET Company Participants Andrew R. Saik - CFO & Treasurer Angela M.
